Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bicycle Therapeutics Plc ADR
(NQ:
BCYC
)
22.42
-0.30 (-1.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bicycle Therapeutics Plc ADR
< Previous
1
2
3
4
5
6
Next >
Bicycle Therapeutics Enhances Leadership Team with Key Appointments
April 03, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
March 28, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
What 8 Analyst Ratings Have To Say About Bicycle Therapeutics
March 01, 2023
Via
Benzinga
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
February 28, 2023
From
Bicycle Therapeutics
Via
Business Wire
Looking Into Bicycle Therapeutics's Return On Capital Employed
November 23, 2022
Via
Benzinga
Recap: Bicycle Therapeutics Q3 Earnings
November 03, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Expert Ratings for Bicycle Therapeutics
August 22, 2022
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Via
Benzinga
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 28, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
February 14, 2023
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 08, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
January 11, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
January 04, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
November 10, 2022
From
Bicycle Therapeutics
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
November 08, 2022
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
November 04, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 03, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
October 10, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics
September 19, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
September 07, 2022
Via
Benzinga
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
September 07, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2022
August 31, 2022
Upgrades
Via
Benzinga
Looking Into Bicycle Therapeutics's Return On Capital Employed
August 22, 2022
According to data from Benzinga Pro, during Q2, Bicycle Therapeutics's (NASDAQ:BCYC) reported sales totaled $4.38 million. Despite a 2.67% increase in earnings, the company posted a loss of $26.83...
Via
Benzinga
Bicycle Therapeutics: Q2 Earnings Insights
August 04, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 04, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
August 02, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
July 28, 2022
Via
Benzinga
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
July 12, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
July 12, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.